公开(公告)号：US20230117133A1

公开(公告)日：2023-04-20

申请号：US18081603

申请日：2022-12-14

Applicant: Myriad Genetics, Inc.

Inventor： Victor Abkevich ,  Kirsten Timms ,  Alexander Gutin ,  Julia Reid

IPC: C12Q1/6886

Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.

公开(公告)号：US20230116885A1

公开(公告)日：2023-04-13

申请号：US17966689

申请日：2022-10-14

Applicant: Myriad Genetics, Inc.

Inventor： Alexander Gutin ,  Julia Reid ,  Ralf Kronenwett ,  Marsel Scheer

IPC: C12Q1/6886 ,  G16H70/60 ,  G16H50/20 ,  G16H20/10 ,  G16B25/10 ,  G16B20/00

Abstract: Provided herein are methods for predicting chemotherapy benefit. The invention predicts chemotherapy benefit based on the expression analysis of biomarkers, e.g., RNA biomarker transcription analysis, taken from a tumor sample. The biomarker expression data can be combined with clinical variables, e.g., tumor size and nodal status, to generate a profile that predicts the benefit of including chemotherapy as a treatment decision.

公开(公告)号：US11505832B2

公开(公告)日：2022-11-22

申请号：US16809338

申请日：2020-03-04

Applicant: MYRIAD GENETICS, INC.

Inventor： Alexander Gutin ,  Julia Reid ,  Ralf Kronenwett ,  Marsel Scheer

IPC: C12Q1/6886 ,  G16H70/60 ,  G16H50/20 ,  G16H20/10 ,  G16B25/10 ,  G16B20/00

Abstract: Provided herein are methods for predicting chemotherapy benefit. The invention predicts chemotherapy benefit based on the expression analysis of biomarkers, e.g., RNA biomarker transcription analysis, taken from a tumor sample. The biomarker expression data can be combined with clinical variables, e.g., tumor size and nodal status, to generate a profile that predicts the benefit of including chemotherapy as a treatment decision.

公开(公告)号：US20220243276A1

公开(公告)日：2022-08-04

申请号：US17575301

申请日：2022-01-13

Applicant: Myriad Genetics, Inc.

Inventor： Alexander Gutin ,  Jerry Lanchbury ,  Susanne Wagner ,  Victor Abkevich

IPC: C12Q1/6886 ,  G16H50/20

Abstract: Methods and compositions involving molecular markers for the detection and characterization of cancer in a patient are provided.

公开(公告)号：US20220205043A1

公开(公告)日：2022-06-30

申请号：US17493826

申请日：2021-10-04

Applicant: Myriad Genetics, Inc.

Inventor： Elisha Hughes ,  Alexander Gutin

IPC: C12Q1/6883 ,  G16B25/00 ,  G16B30/00 ,  C12Q1/6827

Abstract: The present disclosure relates to methods, kits, and systems for assessing the risk of a human subject for developing a cancer, including genetic risk assessment, clinical risk assessment, and combinations of both to improve risk analysis.

公开(公告)号：US20220205022A1

公开(公告)日：2022-06-30

申请号：US17545611

申请日：2021-12-08

Applicant: Myriad Genetics, Inc.

Inventor： Alexander Gutin ,  Kirsten Timms ,  Jerry Lanchbury

IPC: C12Q1/6827 ,  G16B30/00 ,  C12Q1/6858 ,  C12Q1/6874 ,  C12Q1/6883

Abstract: Methods and systems for detecting allelic imbalance using nucleic acid sequencing are provided.

公开(公告)号：US11174517B2

公开(公告)日：2021-11-16

申请号：US15349866

申请日：2016-11-11

Applicant: Myriad Genetics, Inc.

Inventor： Steven Stone ,  Alexander Gutin ,  Julia Reid

IPC: C12Q1/6886

Abstract: Biomarkers and methods using the biomarkers for classifying cancer in a patient (e.g., predicting the risk of cancer-specific death or cancer recurrence) are provided.

公开(公告)号：US20200239943A1

公开(公告)日：2020-07-30

申请号：US16815963

申请日：2020-03-11

Applicant: MYRIAD GENETICS, INC.

Inventor： Alexander Gutin ,  Kirsten Timms ,  Jerry Lanchbury

IPC: C12Q1/6827 ,  C12Q1/6883 ,  C12Q1/6858 ,  C12Q1/6874 ,  G16B30/00

Abstract: Methods and systems for detecting allelic imbalance using nucleic acid sequencing are provided.

公开(公告)号：US20180030544A1

公开(公告)日：2018-02-01

申请号：US15651652

申请日：2017-07-17

Applicant: Myriad Genetics, Inc.

Inventor： Victor Abkevich ,  Kirsten Timms ,  Alexander Gutin

IPC: C12Q1/68 ,  A61K33/24 ,  G06F19/18

CPC classification number: C12Q1/6886 ,  A61K33/24 ,  C12Q1/6827 ,  C12Q1/6858 ,  C12Q2600/106 ,  C12Q2600/154 ,  C12Q2600/156 ,  G16B20/00 ,  C12Q2535/122 ,  C12Q2537/143

Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.

公开(公告)号：US20170198358A1

公开(公告)日：2017-07-13

申请号：US15388979

申请日：2016-12-22

Applicant: Myriad Genetics, Inc.

Inventor： Michael Bryan Warf ,  Benjamin Roa ,  Alexander Gutin ,  Darl Flake

IPC: C12Q1/68 ,  G06F19/20

CPC classification number: C12Q1/6886 ,  C12Q1/6851 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/158 ,  G16B20/00 ,  G16B25/00 ,  C12Q2537/165

Abstract: Panels of biomarkers, methods and systems are disclosed for determining gene expression, and diagnosing and treating melanoma.